{"id":8530,"date":"2026-01-12T06:00:00","date_gmt":"2026-01-11T23:00:00","guid":{"rendered":"https:\/\/www.globenewswire.com\/news-release\/2026\/01\/11\/3216502\/0\/en\/Teva-to-Present-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference-Pivot-to-Growth-Strategy-Delivering-Growth-and-Transforming-through-Innovation.html3216502"},"modified":"2026-01-12T08:34:18","modified_gmt":"2026-01-12T01:34:18","slug":"teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation","status":"publish","type":"post","link":"https:\/\/cryptoinsider.asia\/vi\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\/","title":{"rendered":"Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation"},"content":{"rendered":"\n<p>TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) &#8212; Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44<sup>th<\/sup> Annual J.P. Morgan Healthcare Conference. Teva\u2019s President and Chief Executive Officer, Richard Francis, will meet with investors and present the Company\u2019s milestones achieved in 2025, transformative initiatives, and forward-looking outlook for 2026 and beyond.<\/p>\n<p><strong>Presentation Highlights:<\/strong><\/p>\n<ul type=\"disc\">\n<li><strong>Pivot to Growth Strategy Progress<\/strong>: Teva is accelerating its Pivot to Growth strategy, focusing on transforming into a leading innovative biopharmaceutical company through late-stage innovative pipeline, fueled by its world-class generics business.<\/li>\n<li><strong>Innovation at <\/strong><strong>the <\/strong><strong>Heart<\/strong><strong> of Teva&#8217;s Transformation<\/strong>: Teva&#8217;s key innovative brands \u2013 AUSTEDO<sup>\u00ae<\/sup>, AJOVY<sup>\u00ae<\/sup> and UZEDY<sup>\u00ae<\/sup> \u2013 are already driving its growth and reshaping Teva&#8217;s financial outlook. Teva\u2019s clinical pipeline assets \u2013 olanzapine LAI, DARI (ICS\/SABA), duvakitug (anti-TL1A), emrusolmin, and anti-IL-15 \u2013 are expected to drive Teva&#8217;s long-term growth trajectory and further Teva\u2019s transformation.<\/li>\n<li><strong>2025 Performance<\/strong>: Teva to provide its expected 2025 financial performance.<\/li>\n<li><strong>2026 and <\/strong><strong>B<\/strong><strong>eyond<\/strong>: In addition, Teva to provide forward-looking outlook for 2026 and beyond, underlining disciplined capital allocation and a commitment to securing an investment-grade credit rating.<\/li>\n<\/ul>\n<p><strong>Expected 2025 Performance <\/strong><\/p>\n<div class=\"pcrstb-wrap\"><table>\n<tr>\n<td>\n<p><strong>$ billions, except EPS or as noted<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>2025 Outlook<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Expected 2025 performance relative to Outlook<\/strong><strong> (excl<\/strong><strong>uding <\/strong><strong>duv<\/strong><strong>akitug<\/strong><strong> milestones)<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>Additional contribution from <\/strong><strong>e<\/strong><strong>xpected <\/strong><strong>duvakitug<\/strong><strong> milestones<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"RTL\"><span dir=\"LTR\">Revenues*<\/span><\/p>\n<\/td>\n<td>\n<p>$16.8 &#8211; $17.0<\/p>\n<\/td>\n<td>\n<p>Lower point of the range<\/p>\n<\/td>\n<td>\n<p>$500M<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"RTL\"><span dir=\"LTR\">Operating Margin<\/span><\/p>\n<\/td>\n<td>\n<p>~26.2% &#8211; 27.1%<\/p>\n<\/td>\n<td>\n<p>Mid to high point of the range<\/p>\n<\/td>\n<td>\n<p>~80%-85%<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"RTL\"><span dir=\"LTR\">Adjusted EBITDA<\/span><\/p>\n<\/td>\n<td>\n<p>$4.8 &#8211; $5.0<\/p>\n<\/td>\n<td>\n<p>Midpoint of the range<\/p>\n<\/td>\n<td>\n<p>~$400M-$430M<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>Tax Rate<\/p>\n<\/td>\n<td>\n<p>15%-18%<\/p>\n<\/td>\n<td>\n<p>Lower point of the range<\/p>\n<\/td>\n<td> <\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"RTL\"><span dir=\"LTR\">Diluted EPS ($)<\/span><\/p>\n<\/td>\n<td>\n<p>2.55 &#8211; 2.65<\/p>\n<\/td>\n<td>\n<p>Higher point of the range<\/p>\n<\/td>\n<td> <\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"RTL\"><span dir=\"LTR\">Free Cash Flow**<\/span><\/p>\n<\/td>\n<td>\n<p>$1.6 &#8211; $1.9<\/p>\n<\/td>\n<td>\n<p>Higher point of the range<\/p>\n<\/td>\n<td>\n<p>~$500M<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"RTL\"><span dir=\"LTR\">Net leverage<\/span><\/p>\n<\/td>\n<td>\n<p>~2.5x &#8211; 2.9x<\/p>\n<\/td>\n<td>\n<p>Midpoint of the range<\/p>\n<\/td>\n<td>\n<p>~2.5x<\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p><strong><br \/>P<\/strong><strong>ath to achieving 2027 targets and additional 2030 targets<\/strong><\/p>\n<div class=\"pcrstb-wrap\"><table>\n<tr>\n<td>\n<p><strong>$<\/strong><strong>billions<\/strong><strong>or as n<\/strong><strong>oted<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>2026<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>2027<\/strong><\/p>\n<\/td>\n<td>\n<p><strong>2030<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"RTL\"><span dir=\"LTR\">Revenues*<\/span><\/p>\n<\/td>\n<td>\n<p>Flat to slightly down vs. 2025<\/p>\n<\/td>\n<td>\n<p>Low-single digit growth<\/p>\n<\/td>\n<td>\n<p>Mid-single digit CAGR<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"RTL\"><span dir=\"LTR\">Operating Profit<\/span><\/p>\n<\/td>\n<td rowspan=\"2\">\n<p>Growing vs. 2025<\/p>\n<\/td>\n<td>\n<p>30%<\/p>\n<\/td>\n<td>\n<p>&gt;30%<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"RTL\"><span dir=\"LTR\">Adjusted EBITDA<\/span><\/p>\n<\/td>\n<td>\n<p>Growing vs. 2026<\/p>\n<\/td>\n<td>\n<p>Growing<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"RTL\"><span dir=\"LTR\">Free Cash Flow**<\/span><\/p>\n<\/td>\n<td>\n<p>Growing vs. 2025<\/p>\n<\/td>\n<td>\n<p>&gt;$2.7<\/p>\n<\/td>\n<td>\n<p>&gt;$3.5<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>Net Leverage<\/p>\n<\/td>\n<td>\n<p>~2.0-2.2x<\/p>\n<\/td>\n<td>\n<p>&lt;2x<\/p>\n<\/td>\n<td>\n<p>&lt;2x<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>Cumulative Transformation Programs Savings<\/p>\n<\/td>\n<td>\n<p>~$450M-500M<\/p>\n<\/td>\n<td>\n<p>~$700M<\/p>\n<\/td>\n<td> <\/td>\n<\/tr>\n<\/table><\/div>\n<p><sup>Note: 2026 commentary compared to 2025 results <em>excluding <\/em><em>duvakitug<\/em><em> milestones<\/em><em>, <\/em><em>except for net <\/em><em>deb<\/em><em>t leverage calculation<\/em>. <\/sup><br \/><sup>* Revenues presented on a GAAP basis; all other metrics presented on a non-GAAP basis. <\/sup><br \/><sup>** Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables.<\/sup><\/p>\n<p>To access a live webcast of the presentation, visit Teva\u2019s Investor Relations website at: &nbsp;<span><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_CT6jl4Q0PFkwt2RhJqZKR5icJwSjZEcfMnMLaBAJDQJtEP-O9zfWWmWdmgOF82_LTfDyFXQOC3g6W5jMaboftjt-v8fRNG07XHqfuiz5pTZKAprXT4fQtPzGX6Au1tKezM__8uzJt6GRkYZWh6ohxgmtNibiv4qt_xfX--lEUJPbkx8lZI8PIcj2X87BCSgxb-gqDwxvBfFmd2G3EmAV4c6sdJgKgALy2st20zKzvQnwv6EI5u5giYFCw39ZCQ_qywWxte65mG6MaSHcCK8l9TRMp5vqwQxsGUicbseBS9wA84vOQYjj2hKY2DVKCzd8X9GlSI5JxsjbK58KJ8iK6Xq3ox2hwwe6j32TypX0IkNChmhrVoKdNv5UZyleEAd_16bJybNfrif0hJH_guesA==\" target=\"_blank\" title rel=\"nofollow\">https:\/\/ir.tevapharm.com\/Events-and-Presentations<\/a><\/span>.<\/p>\n<p>An archived version of the webcast will be available within 24 hours after the end of the live discussion and will be accessible for up to 30 days.<\/p>\n<p><strong>About Teva<\/strong><br \/>Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva\u2019s commitment to better health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients\u2019 needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit <span><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QhmfQBEWZplL-8G4yYQk6Vjhf2U4lZ_oSd-coaRXj1hg-v1qBAKRJHo2-pav5qafE-x2PL4JJ7kHQO2aluBSgA8MWVAaF3LfEkvVVyYQFwM=\" target=\"_blank\" title=\"www.tevapharm.com\" rel=\"nofollow\">www.tevapharm.com<\/a><\/span>.<\/p>\n<p><strong>Non-GAAP Financial Measures <\/strong><br \/>This press release includes certain non-GAAP financial measures as defined by SEC rules. Management believes that such non-GAAP financial measures provide useful information to investors to facilitate their understanding of our business because the non-GAAP financial measures are used by Teva&#8217;s management and board of directors, in conjunction with other performance metrics, to evaluate the operational performance of the company, to compare against the company&#8217;s work plans and budgets, and ultimately to evaluate the performance of management; the company\u2019s annual budgets are prepared on a non-GAAP basis; and senior management\u2019s annual compensation is derived, in part, using these non-GAAP measures. Investors should consider the non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. In the case of the non-GAAP financial measures disclosed in this press release, we are not providing comparable forward looking guidance for GAAP financial measures or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measure because we are unable to predict with reasonable certainty the ultimate outcome of certain significant items including, but not limited to, the amortization of purchased intangible assets, legal settlements and loss contingencies, impairment of long-lived assets and goodwill impairment, without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP.<\/p>\n<p><strong>Teva Cautionary Note Regarding Forward Looking Statements<\/strong><br \/>This Press Release and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our financial guidance, which are based on management\u2019s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements include statements concerning our plans, strategies, objectives, future performance and financial and operating targets, and any other information that is not historical information. You can identify these forward-looking statements by the use of words such as \u201cshould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201ctarget,\u201d \u201cmay,\u201d \u201cproject,\u201d \u201cguidance,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d &#8220;outlook\u201d and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; our ability to develop and commercialize additional pharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and the effectiveness of our patents and other measures to protect our intellectual property rights; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this document, in our Quarterly Report on Form 10-Q for the third quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned \u201cRisk Factors\u201d and \u201cForward-looking Statements.\u201d Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.<\/p>\n<p><img decoding=\"async\" alt src=\"https:\/\/ml-eu.globenewswire.com\/media\/YzE3MzRhMWEtMjNjMS00MmFiLWIwMWEtZjc0ZDA1MGFiZTQ0LTEwMTQ2NTAtMjAyNi0wMS0xMS1lbg==\/tiny\/Teva-Pharmaceutical-Industries.png\" referrerpolicy=\"no-referrer-when-downgrade\">  <\/p>\n","protected":false},"excerpt":{"rendered":"<p> Richard Francis, Teva&#8217;s President and CEO, will present at the 44th\u00a0Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) &#8212; Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference. Teva\u2019s President and Chief Executive Officer, Richard Francis, will meet with investors and present the Company\u2019s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":8531,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[75,1406],"tags":[],"class_list":["post-8530","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-globenewswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation<\/title>\n<meta name=\"description\" content=\"Richard Francis, Teva&#039;s President and CEO, will present at the 44th\u00a0Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference. Teva\u2019s President and Chief Executive Officer, Richard Francis, will meet with investors and present the Company\u2019s...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\" \/>\n<meta property=\"og:locale\" content=\"vi_VN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation\" \/>\n<meta property=\"og:description\" content=\"Richard Francis, Teva&#039;s President and CEO, will present at the 44th\u00a0Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference. Teva\u2019s President and Chief Executive Officer, Richard Francis, will meet with investors and present the Company\u2019s...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cryptoinsider.asia\/vi\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\/\" \/>\n<meta property=\"og:site_name\" content=\"Crypto Insider\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/yourcryptoinsider\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-11T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T01:34:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/YzE3MzRhMWEtMjNjMS00MmFiLWIwMWEtZjc0ZDA1MGFiZTQ0LTEwMTQ2NTAtMjAyNi0wMS0xMS1lbg==\/tiny\/Teva-Pharmaceutical-Industries.png\" \/>\n<meta name=\"author\" content=\"Crypto Insider\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u0110\u01b0\u1ee3c vi\u1ebft b\u1edfi\" \/>\n\t<meta name=\"twitter:data1\" content=\"Crypto Insider\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u01af\u1edbc t\u00ednh th\u1eddi gian \u0111\u1ecdc\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 ph\u00fat\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\\\/\"},\"author\":{\"name\":\"Crypto Insider\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/#\\\/schema\\\/person\\\/e81ca31713268a414ddbed321d3383d6\"},\"headline\":\"Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation\",\"datePublished\":\"2026-01-11T23:00:00+00:00\",\"dateModified\":\"2026-01-12T01:34:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\\\/\"},\"wordCount\":1197,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation.gif\",\"articleSection\":[\"Business\",\"GlobeNewswire\"],\"inLanguage\":\"vi\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\\\/\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\\\/\",\"name\":\"Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation - Crypto Insider\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation.gif\",\"datePublished\":\"2026-01-11T23:00:00+00:00\",\"dateModified\":\"2026-01-12T01:34:18+00:00\",\"description\":\"Crypto and Blockchain News\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\\\/#breadcrumb\"},\"inLanguage\":\"vi\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"vi\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation.gif\",\"contentUrl\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation.gif\",\"width\":1,\"height\":1},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cryptoinsider.asia\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/cryptoinsider.asia\\\/category\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Business\",\"item\":\"https:\\\/\\\/cryptoinsider.asia\\\/category\\\/business\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#website\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/\",\"name\":\"Crypto Insider\",\"description\":\"Crypto and Blockchain News\",\"publisher\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"vi\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#organization\",\"name\":\"Crypto Insider\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"vi\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Logo-crypto-insider.jpeg\",\"contentUrl\":\"https:\\\/\\\/cryptoinsider.asia\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Logo-crypto-insider.jpeg\",\"width\":2048,\"height\":2048,\"caption\":\"Crypto Insider\"},\"image\":{\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/vi\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/yourcryptoinsider\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/vietnaminsider\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cryptoinsider.asia\\\/#\\\/schema\\\/person\\\/e81ca31713268a414ddbed321d3383d6\",\"name\":\"Crypto Insider\",\"description\":\"Tin t\u1ee9c v\u1ec1 Ti\u1ec1n \u0111i\u1ec7n t\u1eed v\u00e0 c\u00f4ng ngh\u1ec7 Blockchain\",\"sameAs\":[\"https:\\\/\\\/cryptoinsider.asia\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation","description":"Richard Francis, Teva's President and CEO, will present at the 44th\u00a0Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference. Teva\u2019s President and Chief Executive Officer, Richard Francis, will meet with investors and present the Company\u2019s...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"Richard Francis, Teva's President and CEO, will present at the 44th\u00a0Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference. Teva\u2019s President and Chief Executive Officer, Richard Francis, will meet with investors and present the Company\u2019s...","og_locale":"vi_VN","og_type":"article","og_title":"Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation","og_description":"Richard Francis, Teva's President and CEO, will present at the 44th\u00a0Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference. Teva\u2019s President and Chief Executive Officer, Richard Francis, will meet with investors and present the Company\u2019s...","og_url":"https:\/\/cryptoinsider.asia\/vi\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\/","og_site_name":"Crypto Insider","article_publisher":"https:\/\/www.facebook.com\/yourcryptoinsider","article_published_time":"2026-01-11T23:00:00+00:00","article_modified_time":"2026-01-12T01:34:18+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/YzE3MzRhMWEtMjNjMS00MmFiLWIwMWEtZjc0ZDA1MGFiZTQ0LTEwMTQ2NTAtMjAyNi0wMS0xMS1lbg==\/tiny\/Teva-Pharmaceutical-Industries.png","type":"","width":"","height":""}],"author":"Crypto Insider","twitter_card":"summary_large_image","twitter_misc":{"\u0110\u01b0\u1ee3c vi\u1ebft b\u1edfi":"Crypto Insider","\u01af\u1edbc t\u00ednh th\u1eddi gian \u0111\u1ecdc":"6 ph\u00fat"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cryptoinsider.asia\/vi\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\/#article","isPartOf":{"@id":"https:\/\/cryptoinsider.asia\/vi\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\/"},"author":{"name":"Crypto Insider","@id":"https:\/\/cryptoinsider.asia\/#\/schema\/person\/e81ca31713268a414ddbed321d3383d6"},"headline":"Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation","datePublished":"2026-01-11T23:00:00+00:00","dateModified":"2026-01-12T01:34:18+00:00","mainEntityOfPage":{"@id":"https:\/\/cryptoinsider.asia\/vi\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\/"},"wordCount":1197,"commentCount":0,"publisher":{"@id":"https:\/\/cryptoinsider.asia\/#organization"},"image":{"@id":"https:\/\/cryptoinsider.asia\/vi\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\/#primaryimage"},"thumbnailUrl":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2026\/01\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation.gif","articleSection":["Business","GlobeNewswire"],"inLanguage":"vi","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cryptoinsider.asia\/vi\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cryptoinsider.asia\/vi\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\/","url":"https:\/\/cryptoinsider.asia\/vi\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\/","name":"Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation - Crypto Insider","isPartOf":{"@id":"https:\/\/cryptoinsider.asia\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cryptoinsider.asia\/vi\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\/#primaryimage"},"image":{"@id":"https:\/\/cryptoinsider.asia\/vi\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\/#primaryimage"},"thumbnailUrl":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2026\/01\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation.gif","datePublished":"2026-01-11T23:00:00+00:00","dateModified":"2026-01-12T01:34:18+00:00","description":"Crypto and Blockchain News","breadcrumb":{"@id":"https:\/\/cryptoinsider.asia\/vi\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\/#breadcrumb"},"inLanguage":"vi","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cryptoinsider.asia\/vi\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\/"]}]},{"@type":"ImageObject","inLanguage":"vi","@id":"https:\/\/cryptoinsider.asia\/vi\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\/#primaryimage","url":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2026\/01\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation.gif","contentUrl":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2026\/01\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation.gif","width":1,"height":1},{"@type":"BreadcrumbList","@id":"https:\/\/cryptoinsider.asia\/vi\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cryptoinsider.asia\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/cryptoinsider.asia\/category\/news\/"},{"@type":"ListItem","position":3,"name":"Business","item":"https:\/\/cryptoinsider.asia\/category\/business\/"},{"@type":"ListItem","position":4,"name":"Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation"}]},{"@type":"WebSite","@id":"https:\/\/cryptoinsider.asia\/vi\/#website","url":"https:\/\/cryptoinsider.asia\/vi\/","name":"Crypto Insider","description":"Crypto and Blockchain News","publisher":{"@id":"https:\/\/cryptoinsider.asia\/vi\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cryptoinsider.asia\/vi\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"vi"},{"@type":"Organization","@id":"https:\/\/cryptoinsider.asia\/vi\/#organization","name":"Crypto Insider","url":"https:\/\/cryptoinsider.asia\/vi\/","logo":{"@type":"ImageObject","inLanguage":"vi","@id":"https:\/\/cryptoinsider.asia\/vi\/#\/schema\/logo\/image\/","url":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2021\/11\/Logo-crypto-insider.jpeg","contentUrl":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2021\/11\/Logo-crypto-insider.jpeg","width":2048,"height":2048,"caption":"Crypto Insider"},"image":{"@id":"https:\/\/cryptoinsider.asia\/vi\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/yourcryptoinsider","https:\/\/www.linkedin.com\/company\/vietnaminsider"]},{"@type":"Person","@id":"https:\/\/cryptoinsider.asia\/#\/schema\/person\/e81ca31713268a414ddbed321d3383d6","name":"Crypto Insider","description":"Tin t\u1ee9c v\u1ec1 Ti\u1ec1n \u0111i\u1ec7n t\u1eed v\u00e0 c\u00f4ng ngh\u1ec7 Blockchain","sameAs":["https:\/\/cryptoinsider.asia"]}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/cryptoinsider.asia\/wp-content\/uploads\/2026\/01\/teva-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-pivot-to-growth-strategy-delivering-growth-and-transforming-through-innovation.gif","jetpack-related-posts":[],"jetpack_likes_enabled":false,"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/posts\/8530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/comments?post=8530"}],"version-history":[{"count":0,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/posts\/8530\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/media\/8531"}],"wp:attachment":[{"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/media?parent=8530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/categories?post=8530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cryptoinsider.asia\/vi\/wp-json\/wp\/v2\/tags?post=8530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}